50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#42

Retatrutide

Weight ManagementLY3437943GGG Triple Agonist

A triple-acting agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, representing the next evolution in incretin-based obesity treatment with the highest weight loss observed in clinical trials to date.

Share:

Overview

Retatrutide is a novel triple hormone receptor agonist developed by Eli Lilly that simultaneously activates three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This triple mechanism represents an evolution beyond the dual GIP/GLP-1 agonism of tirzepatide, adding glucagon receptor activation to further enhance metabolic effects, particularly fat burning and energy expenditure.

The addition of glucagon receptor agonism is a bold pharmacological strategy. Glucagon has historically been associated with raising blood sugar and was considered counterproductive in diabetes treatment. However, at the doses and in the context of combined GIP/GLP-1 activation, glucagon receptor stimulation adds significant energy expenditure and lipolytic effects. It may also contribute to reduced food intake and improved liver fat metabolism. The balance of these three hormone signals appears to produce weight loss exceeding that of any previous pharmacological approach.

Phase 2 clinical trial results for retatrutide generated enormous excitement. In the study published in the New England Journal of Medicine in 2023, the highest dose group (12 mg weekly) achieved mean weight loss of 24.2% at 48 weeks — the highest weight loss ever reported for a pharmacological agent in a clinical trial. Nearly 100% of participants in the highest dose group lost at least 5% of their body weight, and over 25% lost more than 30% of their body weight.

Phase 3 trials are ongoing, and if results confirm the phase 2 findings, retatrutide could become the most effective anti-obesity medication ever developed. Beyond weight loss, the phase 2 trial showed significant improvements in glycemic control, blood pressure, and lipid parameters. Research is also exploring retatrutide for non-alcoholic steatohepatitis (NASH) and other metabolic conditions. The drug represents the cutting edge of incretin-based therapy and the pharmaceutical industry's aggressive pursuit of more effective obesity treatments.

Research Uses & Applications

  • Under clinical development for chronic weight management
  • Investigated for type 2 diabetes treatment
  • Studied for non-alcoholic steatohepatitis (NASH/MASH)
  • Explored for comprehensive metabolic syndrome improvement
  • Research into triple-agonist approach for cardiovascular risk reduction
  • Being evaluated for sleep apnea and other obesity-related conditions

Key Research Findings

  • Phase 2 trial showed mean weight loss of 24.2% at 48 weeks with the 12 mg weekly dose, the highest for any pharmacological agent in trials (NEJM, 2023).
  • Nearly 100% of high-dose participants achieved at least 5% weight loss, with over 25% losing more than 30% body weight.
  • The trial demonstrated significant HbA1c reductions in participants with type 2 diabetes.
  • Retatrutide showed substantial improvements in cardiovascular risk factors including blood pressure, triglycerides, and liver enzymes.
  • The glucagon receptor agonist component appeared to contribute additional energy expenditure and hepatic fat reduction beyond dual GIP/GLP-1 agonism.

Risks & Side Effects

  • Gastrointestinal side effects (nausea, diarrhea, vomiting, constipation) are common, consistent with the drug class.
  • The glucagon receptor component raises theoretical concerns about blood glucose elevation, though this was not clinically significant in trials.
  • Long-term safety data is not yet available as the drug is still in clinical development.
  • Potential for muscle mass loss alongside fat loss at these extreme weight reduction levels.
  • Not yet approved; efficacy and safety need confirmation in phase 3 trials.

Administration

Administered as a once-weekly subcutaneous injection in clinical trials. Phase 2 dosing ranged from 0.5 mg to 12 mg weekly, with gradual dose escalation. The phase 3 program will establish optimal dosing regimens. Not yet commercially available.

Legal Status

Retatrutide is an investigational drug in clinical development by Eli Lilly. It is not approved by any regulatory agency. Phase 3 clinical trials are ongoing. It is not available for purchase. Estimated regulatory submission and potential approval timelines have not been publicly confirmed.

Frequently Asked Questions

What is Retatrutide?

A triple-acting agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, representing the next evolution in incretin-based obesity treatment with the highest weight loss observed in clinical trials to date.

What are the main uses of Retatrutide?

The primary research applications of Retatrutide include: Under clinical development for chronic weight management; Investigated for type 2 diabetes treatment; Studied for non-alcoholic steatohepatitis (NASH/MASH); Explored for comprehensive metabolic syndrome improvement; Research into triple-agonist approach for cardiovascular risk reduction; Being evaluated for sleep apnea and other obesity-related conditions.

What are the risks and side effects of Retatrutide?

Documented risks and side effects include: Gastrointestinal side effects (nausea, diarrhea, vomiting, constipation) are common, consistent with the drug class.; The glucagon receptor component raises theoretical concerns about blood glucose elevation, though this was not clinically significant in trials.; Long-term safety data is not yet available as the drug is still in clinical development.; Potential for muscle mass loss alongside fat loss at these extreme weight reduction levels.; Not yet approved; efficacy and safety need confirmation in phase 3 trials.. Always consult a healthcare professional before considering any peptide.

Is Retatrutide legal?

Retatrutide is an investigational drug in clinical development by Eli Lilly. It is not approved by any regulatory agency. Phase 3 clinical trials are ongoing. It is not available for purchase. Estimated regulatory submission and potential approval timelines have not been publicly confirmed.

How is Retatrutide administered?

Administered as a once-weekly subcutaneous injection in clinical trials. Phase 2 dosing ranged from 0.5 mg to 12 mg weekly, with gradual dose escalation. The phase 3 program will establish optimal dosing regimens. Not yet commercially available.

Related Peptides

#2

Semaglutide

Weight Management

#3

Tirzepatide

Weight Management

#10

AOD-9604

Weight Management

#27

Liraglutide

Weight Management

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #41 Glutathione#43 Survodutide →